Practicing responsible prescribing, Vida supports patients, employers, and health plans by prioritizing proven behavior change and lifestyle interventions before introducing medications, ensuring that only those who need anti-obesity medications receive them helping to control costs
Potential Benefits: May stimulate lipolysis via beta-3 adrenergic pathways Does not appear to affect blood pressure or glucose significantly Phase IIb data suggests modest fat loss with diet/exercise Suggested Clinical Dosing Range: 11.8 mg daily subcutaneous Dosing is individualized and determined by a qualified medical provider
These constraints are translated into a deficient extracellular post-translational modification, basically at the level of the cleavage of the C propeptide, catalyzed by BMP1, and the formation of covalent cross-links, initiated by LOX enzymes 5,6
Results continue accumulating through week 48 in clinical trial data
For meaningful biological activity, look for oils with verified polyphenol content of at least 500 mg/kg